Influence of Shengmaiyin Combined with Xuefu Zhuyu Tang on Hypercoagulable State Caused by Non-small Cell Lung Cancer

Lan ZHANG; Lei SONG; De-xu LI; Ya-wei LIU; Yong-chen ZHAO; Gui-min YANG; Min TANG

doi:10.13422/j.cnki.syfjx.201901132

您当前的位置：

首页 >

文章列表页 >

Influence of Shengmaiyin Combined with Xuefu Zhuyu Tang on Hypercoagulable State Caused by Non-small Cell Lung Cancer

Clinic | 更新时间：2021-02-09

- Influence of Shengmaiyin Combined with Xuefu Zhuyu Tang on Hypercoagulable State Caused by Non-small Cell Lung Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 11, Pages: 109-114(2019)
- 作者机构：
  
  1.河北大学　附属医院，河北　保定　 071006；
  2.保定市第一医院，河北　保定　 071015；
  3.保定市儿童医院，河北　保定　 071011
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.201901132
  CLC： R25; R289; R273; R734
- Received：29 November 2018，
  
  Published Online：16 January 2019，
  
  Published：05 June 2019
- 稿件说明：
移动端阅览
Lan ZHANG, Lei SONG, De-xu LI, et al. Influence of Shengmaiyin Combined with Xuefu Zhuyu Tang on Hypercoagulable State Caused by Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(11): 109-114.
DOI：

Lan ZHANG, Lei SONG, De-xu LI, et al. Influence of Shengmaiyin Combined with Xuefu Zhuyu Tang on Hypercoagulable State Caused by Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(11): 109-114. DOI： 10.13422/j.cnki.syfjx.201901132.

摘要

目的：

观察生脉饮合血府逐瘀汤加减对非小细胞肺癌(NSCLC)高凝状态患者纤溶活性和凝血活性因子的影响。

方法：

选取NSCLC 高凝状态患者118例，随机按数字表法分为观察组60例和对照组58例。对照组采用低分子肝素钙注射液，1.0 mL(5 000 AXa)/次，1次/d，皮下注射，连续使用3周；口服阿司匹林肠溶片，100 mg/次，1次/d。观察组采用生脉饮合血府逐瘀汤加减，1剂/d。两组患者均连续治疗8周。检测活化部分凝血活酶时间(APTT)，凝血酶原时间(PT)，凝血酶时间(TT)，血小板(PLT)，纤维蛋白原(FIB)，

-二聚体(D-D)，血浆组织纤溶酶原激活物(t-PA)，血浆纤溶酶原激活物抑制剂-1(PAI-1)，血管假性血友病因子(vWF)，P-选择素，碱性成纤维细胞生长因子(bFGF)，转化生长因子(TGF)和血管内皮生长因子(VEGF)水平，进行治疗前后气虚血瘀证评分和血液流变学指标检测。

结果：

治疗后观察组APTT，PT，TT均长于对照组，FIB水平低于对照组(

0.05)；观察组PLT，

-D和PAI-1水平均低于对照组(

0.01)，t-PA水平高于对照组(

0.01)；治疗后观察组vWF，P-选择素，bFGF，TGF和VEGF水平均低于对照组(

0.05，

0.01)；治疗后观察组全血黏度(高切、低切)以及血浆黏度、血小板聚集率等血液流变学指标的改善均优于对照组(

0.01)；治疗后观察组患者各气虚症状评分均明显低于对照组(

0.01)，观察组除“癥积”外，其他血瘀症状评分均明显低于对照组(

0.01)。

结论：

生脉饮合血府逐瘀汤加减能改善NSCLC 的高凝状态，减轻临床症状，能调节纤溶活性、凝血活性因子，从而降低了NSCLC深静脉血栓形成的危险。

Abstract

Objective:

To observe influence of dialectical addition and subtraction of Shengmaiyin combined with Xuefu Zhuyu Tang on fibrinolytic activity and coagulation active factor of patients with non-small cell lung cancer at hypercoagulable state.

Method:

One hundred and eighty patients were randomly divided into control group (58 cases) and observation group (60 cases) by random number table. Patients in control group got low molecular weight heparins calcium injection by subcutaneous injection for 3 weeks

1.0 mL (5 000 AXa unit)/time

1 time/day

and oral aspirin enteric-coated tablets

100 mg/time

1 time/day. Patients in observation group got dialectical addition and subtraction of Shengmaiyin combined with Xuefu Zhuyu Tang

1 dose/day. A course of treatment was 8 weeks. And activated partial thromboplastin time (APTT)

prothrombin time (PT)

thrombin time (TT)

platelet (PLT)

fibrinogen (FIB)

-dimer (D-D)

plasma tissue plasminogen activator (t-PA)

plasminogen activator inhibitor in plasma-1 (PAI-1)

von willebrand factor (vWF)

P-selectin

basic fibroblast growth factor (bFGF)

transforming growth factor (TGF)

vascular endothelial growth factor (VEGF) were detected. And before and after treatment

scores of Qi deficiency and blood stasis syndrome and hemorheological indices were detected.

Result:

After treatment

APTT

PT and TT in observation group were longer than those in control group. Levels of PLT

D-D and PAI-1 were lower than those in control group (

0.01)

level of t-PA was higher than that in control group (

0.01). And levels of vWF

P-selectin

bFGF

TGF and VEGF were lower than those in control group (

0.05

0.01). And improvement of hemorheological indexes the such as the whole blood viscosity (high shear and low shear)

plasma viscosity and platelet aggregation rate were better than those in control group (

0.01). And scores of symptoms of Qi deficiency were lower than those in control group (

0.01)

and except for 'zhengji’

scores of symptoms of blood stasis were lower than those in lower than those in control group (

0.01).

Conclusion:

Dialectical addition and subtraction of Shengmaiyin combined with Xuefu Zhuyu Tang can ameliorate hypercoagulable state of NSCLC

relieve clinical symptoms

and can regulate fibrinolytic activity and coagulation activity factors

so it can mitigate dangers caused by deep venous thrombosis of NSCLC.

关键词

Keywords

references

赵铎，高宝安．中晚期非小细胞肺癌联合治疗研究进展 [J]．海南医学， 2016 ， 27 ( 3 )： 438 - 441 ．

韩荣龙，周家明，胡陵静．癌康宁合剂对晚期非小细胞肺癌化疗后患者维持治疗的临床评价 [J]．中国实验方剂学杂志， 2018 ， 24 ( 19 )： 201 - 206 ．

郑丽新，赵明，王玉，等．高凝状态对非小细胞肺癌患者深静脉血栓形成的影响 [J]．现代生物医学进展， 2014 ， 14 ( 29 )： 5699 - 5701 ．

韩啸东，张侠，刘畅，等．非小细胞肺癌患者血液高凝状态的临床调查 [J]．现代生物医学进展， 2015 ， 15 ( 5 )： 877，882-886 ．

曲洪澜．晚期非小细胞肺癌患者血浆纤维蛋白原，D-二聚体水平与预后的相关性分析 [J]．重庆医学， 2015 ， 44 ( 19 )： 2665 - 2667 ．

李丛煌，刘瑞，郑红刚，等．晚期非小细胞肺癌中医证候分布及动态演变临床研究 [J]．中医学报， 2015 ， 30 ( 8 )： 1085 - 1088 ．

胡玲，苏雷，张迎舟，等．银杏叶提取物注射液对肺癌化疗患者血液高凝状态的影响 [J]．中国实验方剂学杂志， 2014 ， 20 ( 19 )： 194 - 197 ．

成娅婷，田成旺，任涛，等．中药治疗非小细胞肺癌的临床应用及作用机制研究进展 [J]．药物评价研究， 2016 ， 39 ( 2 )： 289 - 295 ．

杨爱武，吕宏升，张江灵，等．生脉散加味对晚期肺腺癌患者化疗毒副反应及临床症状、生活质量的影响 [J]．现代中西医结合杂志， 2016 ， 25 ( 33 )： 3735 - 3737 ．

张红，李媛，廖淑芬．抗肿瘤常规方案联合血府逐瘀汤治疗中晚期非小细胞肺癌血液高凝状态30例 [J]．湖南中医杂志， 2018 ， 34 ( 6 )： 67 - 68 ．

支修益，石远凯，于金明．中国原发性肺癌诊疗规范(2015年版) [J]．中华肿瘤杂志， 2015 ， 37 ( 1 )： 67 - 78 ．

郑洋，孙霈，董青，等．恶性肿瘤高凝状态发病机理与诊断标准探讨 [J]．中国医刊， 2014 ， 49 ( 5 )： 16 - 20 ．

刘永衡，张培彤，孔凡君．中晚期原发性肺癌血瘀证分级量化标准的临床研究 [J]．山东中医药大学学报， 2010 ， 51 ( 2 )： 125 - 129 ．

王静，张侠．恶性肿瘤患者高凝状态的危险因素、发生机制及实验室检测 [J]．检验医学与临床， 2015 ， 12 ( 15 )： 2284 - 2287 ．

逄艳，张芳．补阳还五汤改善晚期肺癌高凝状态的临床研究 [J]．云南中医中药杂志， 2017 ， 38 ( 7 )： 33 - 34 ．

胡传杏子．祛瘀汤治疗晚期非小细胞肺癌高凝状态气虚血瘀证的临床研究 [J]．陕西中医， 2016 ， 37 ( 3 )： 288 - 290 ．

钱丽燕，郭勇．恶性肿瘤高凝状态——血瘀证——活血化瘀的思考 [J]．中华中医药学刊， 2013 ， 31 ( 4 )： 856 - 858 ．

Hahn N , Heiden M , Seitz R , et al . Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion [J]. Cancer Res Clin Oncol , 2012 , 138 ( 4 ): 695 - 703 .

邱星安，宁军，黄乙江．血府逐瘀汤对终末期肾病维持性血液透析患者血液高凝状态的影响 [J]．中国实验方剂学杂志， 2015 ， 21 ( 14 )： 153 - 156 ．

Ay C , Dunkler D , Pirker R , et al . High D-dimer levels are associated with poor prognosis in cancer patients [J]. Haematologica , 2012 , 97 ( 8 ): 1158 - 1164 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer via Nrf2/ROS Pathway

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress via Nrf2/ROS/PERK/CHOP Signaling Pathway to Attenuate Cisplatin Resistance in NSCLC

Construction and Verification of Prediction Model of Qi Deficiency and Blood Stasis Syndrome in Chronic Heart Failure

Effect of Yiqi Huoxue Prescription on cAMP/Epac1/Rap1 Signaling Pathway in Coronary Heart Disease Rats with Qi Deficiency and Blood Stasis Syndrome

Buzhong Yiqitang Regulates Apoptosis via Nrf2/ROS Pathway to Alleviate Cisplatin Resistance in A549/DDP Cells

Related Author

YU Dan

MU Qirui

LI He

LIU Yuetong

HUANG Jingyi

GAO Yuan

LI He

LIU Yuetong

Related Institution

College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

Dongzhimen Hospital， Beijing University of Chinese Medicine

Binzhou Medical University

Key Laboratory of Chinese Internal Medicine of Ministry of Education，Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰